Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
167
-
Total 13F shares, excl. options
-
162M
-
Shares change
-
-21.5M
-
Total reported value, excl. options
-
$201M
-
Value change
-
-$24.3M
-
Put/Call ratio
-
0.47
-
Number of buys
-
89
-
Number of sells
-
-52
-
Price
-
$1.24
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q3 2025
187 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q3 2025.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 167 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 162M shares
of 226M outstanding shares and own 71.66% of the company stock.
Largest 10 shareholders include Pfizer Inc (22M shares), TPG GP A, LLC (18.7M shares), BlackRock, Inc. (17.5M shares), CITADEL ADVISORS LLC (14M shares), VANGUARD GROUP INC (9.02M shares), PRIMECAP MANAGEMENT CO/CA/ (7.08M shares), Woodline Partners LP (4.36M shares), Frazier Life Sciences Management, L.P. (3.87M shares), GEODE CAPITAL MANAGEMENT, LLC (3.83M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (3.68M shares).
This table shows the top 167 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.